Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration resistant prostate cancer and resistance to AR targeting therapies including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease.
- Received May 26, 2016.
- Accepted May 26, 2016.
- Copyright ©2016, American Association for Cancer Research.